RecruitingPhase 2NCT07029529
Phase 2 Study of Apremilast in Women and Men With Alcohol Use Disorder
Sponsor
Yale University
Enrollment
80 participants
Start Date
May 12, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
For this protocol, the investigators plan to collect data to evaluate apremilast (60mg/day) vs placebo in adults with Alcohol Use Disorders (AUD).
Eligibility
Min Age: 21 YearsMax Age: 65 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Apremilast 60mg and Placebo for people with alcohol use disorder. The study is currently recruiting participants at 1 location. People eligible for this study include aged 21 Years to 65 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGApremilast 60mg
Apremilast 60mg/day
OTHERPlacebo
Placebo
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07029529
Related Trials
Environment and Alcohol: A Pilot Study
NCT068606071 location
Hepatic Lipid Metabolism-Alcohol Use Disorder
NCT071915611 location
Tirzepatide in MetALD
NCT070468191 location
Screening, Evaluation and Assessment (SEA) Protocol at the NIDA IRP
NCT065527411 location
Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder
NCT062696271 location